Glutamate protects neuromuscular junctions from deleterious effects of β-amyloid peptide and conversely: An in vitro study in a nerve-muscle coculture

Journal of Neuroscience Research

Volumn 93, Issue 4, 2015, Pages 633-643

  Combes, Maud ^a   Poindron, Philippe ^a   Callizot, Noelle ^a  

^a Department of Research and Development Neuro Sys SAS   (France)

Author keywords

ALS; Amyloid peptide; Glutamate; NMDAR; NMJ

Indexed keywords

AMYLOID BETA PROTEIN; CASPASE 3; DIZOCILPINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; AMINO ACID RECEPTOR STIMULATING AGENT; AMYLOID BETA-PROTEIN (1-42); NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN H; PEPTIDE FRAGMENT;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROTECTION; COCULTURE; CONTROLLED STUDY; EMBRYO; EXCITOTOXICITY; IN VITRO STUDY; MUSCLE FIBER CULTURE; MUSCLE INNERVATION; NERVE CELL CULTURE; NEURITE; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; RAT; ANALYSIS OF VARIANCE; ANIMAL; CYTOLOGY; DRUG EFFECTS; HUMAN; METABOLISM; MUSCLE; NERVE CELL; NEWBORN; SPINAL CORD; SPINAL GANGLION; WISTAR RAT;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; CASPASE 3; COCULTURE TECHNIQUES; EXCITATORY AMINO ACID AGONISTS; GANGLIA, SPINAL; GLUTAMIC ACID; HUMANS; IN VITRO TECHNIQUES; MUSCLES; NEUROFILAMENT PROTEINS; NEUROMUSCULAR JUNCTION; NEURONS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; SPINAL CORD;

EID: 84922964122     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23524     Document Type: Article

References (43)

1. Akaaboune M, Allinquant B, Farza H, Roy K, Magoul R, Fiszman M, Festoff BW, Hantaï D. 2000. Developmental regulation of amyloid precursor protein at the neuromuscular junction in mouse skeletal muscle. Mol Cell Neurosci 15:355-367.
2. Askanas V, Kwan H, Alvarez RB, Engel WK, Kobayashi T, Martinuzzi A, Hawkins EF. 1987. De novo neuromuscular junction formation on human muscle fibres cultured in monolayer and innervated by foetal rat spinal cord: ultrastructural and ultrastructural-cytochemical studies. J Neurocytol 16:523-537.
3. Bishop GM, Robinson SR. 2004. Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease. Drugs Aging 21:621-630.
4. Bordji K, Becerril-Ortega J, Nicole O, Buisson A. 2010. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ß production. J Neurosci 24:15927-15942.
5. Braun S, Croizat B, Lagrange MC, Warter JM, Poindron P. 1996. Neurotrophins increase motoneurons' ability to innervate skeletal muscle fibers in rat spinal cord-human muscle cocultures. J Neurol Sci 136:17-23.
6. Bryson JB, Hobbs C, Parsons MJ, Bosch KD, Pandraud A, Walsh FS, Doherty P, Greensmith L. 2012. Amyloid precursor protein (APP) contributes to pathology in the SOD1 (G93A) mouse model of amyotrophic lateral sclerosis. Hum Mol Genet 21:3871-3882.
7. Butterfield DA, Pocernich CB. 2003. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs 17:641-652.
8. Caldwell JH, Klevanski M, Saar M, Müller UC. 2013. Roles of the amyloid precursor protein family in the peripheral nervous system. Mech Dev 130:433-446.
9. Calingasan, NY, Chen J, Kiaei M, Beal MF. 2005. Beta-amyloid 42 accumulation in the lumbar spinal cord motor neurons of amyotrophic lateral sclerosis patients. Neurobiol Dis 19:340-347.
10. Callizot N, Combes M, Steinschneider R, Poindron P. 2013. Operational dissection of β-amyloid cytopathic effects on cultured neurons. J Neurosci Res 91:706-716.
11. Danysz W, Parsons CG. 2012. Alzheimer's disease, β-amyloid, glutamate, NMDA receptors, and memantine: searching for the connections. Br J Pharmacol 167:324-352.
12. Gerardo-Nava J, Mayorenko II, Grehl T, Steinbusch HW, Weis J, Brook GA. 2013. Differential pattern of neuroprotection in lumbar, cervical, and thoracic spinal cord segments in an organotypic rat model of glutamate-induced excitotoxicity. J Chem Neuroanat 53:11-17.
13. Giedraitis V, Sundelöf J, Irizarry MC, Gårevik N, Hyman BT, Wahlund LO, Ingelsson M, Lannfelt L. 2007. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett 427:127-131.
14. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A. 2009. Beta-amyloid monomers are neuroprotective. J Neurosci 29:10582-10587.
15. Giuffrida ML, Caraci F, De Bona P, Pappalardo G, Nicoletti F, Rizzarelli E, Copani A. 2010. The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. Rev Neurosci 21:83-93.
16. Hardingham GE. 2009. Decoupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans 37:1147-1160.
17. Hardingham GE, Bading H. 2010. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11:682-696.
18. Itkin A, Dupres V, Dufrêne YF, Bechinger B, Ruysschaert JM, Raussens V. 2011. Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS One 28:e18250.
19. Kawahara M. 2010. Neurotoxicity of β-amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis. Curr Pharm Des 16:2779-2789.
20. Koistinen H, Prinjha R, Soden P, Harper A, Banner SJ, Pradat PF, Loeffler JP, Dingwall C. 2006. Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. Muscle Nerve 34:444-450.
21. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. 2011. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 31:6627-6638.
22. López-Toledano MA, Shelanski ML. 2004. Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. J Neurosci 24:5439-5444.
23. Lundgren JL, Ahmed S, Winblad B, Gouras GK, Tjernberg LO, Frykman S. 2014. Activity-independent release of the amyloid β-peptide from rat brain nerve terminals. Neurosci Lett 30:125-130.
24. Malm T, Ort M, Tähtivaara L, Jukarainen N, Goldsteins G, Puoliväli J, Nurmi A, Pussinen R, Ahtoniemi T, Miettinen TK, Kanninen K, Leskinen S, Vartiainen N, Yrjänheikki J, Laatikainen R, Harris-White ME, Koistinaho M, Frautschy SA, Bures J, Koistinaho J. 2006. Beta-amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. Proc Natl Acad Sci U S A 103:8852-8857.
25. Malomouzh AI, Nurullin LF, Arkhipova SS, Nikolsky EE. 2011. NMDA receptors at the endplate of rat skeletal muscles: precise postsynaptic localization. Muscle Nerve 44:987-989.
26. Mays TA, Sanford JL, Hanada T, Chishti AH, Rafael-Fortney JA. 2009. Glutamate receptors localize postsynaptically at neuromuscular junctions in mice. Muscle Nerve 39:343-349.
27. Mura E, Zappettini S, Preda S, Biundo F, Lanni C, Grilli M, Cavallero A, Olivero G, Salamone A, Govoni S, Marchi M. 2012. Dual effect of beta-amyloid on α7 and α4β2 nicotinic receptors controlling the release of glutamate, aspartate, and GABA in rat hippocampus. PLoS One 7:e29661.
28. Palop JJ, Mucke L. 2010. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13:812-818.
29. Park S, Nozaki K, Smith JA, Krause JS, Banik NL. 2014. Cross-talk between IGF-1 and estrogen receptors attenuates intracellular changes in ventral spinal cord motoneuron cells because of interferon-gamma exposure. J Neurochem 128:904-918.
30. Puzzo D, Arancio O. 2013. Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? J Alzheimers Dis 33:S111-S120.
31. Puzzo D, Privitera L, Leznik E, Fà M, Staniszewski A, Palmeri A, Arancio O. 2008. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28:14537-14545.
32. Rebolledo DL, Aldunate R, Kohn R, Neira I, Minniti AN, Inestrosa NC. 2011. Copper reduces Aβ oligomeric species and ameliorates neuromuscular synaptic defects in a C. elegans model of inclusion body myositis. J Neurosci 31:10149-10158.
33. Sen I, Nalini A, Joshi NB, Joshi PG. 2005. Cerebrospinal fluid from amyotrophic lateral sclerosis patients preferentially elevates intracellular calcium and toxicity in motor neurons via AMPA/kainate receptor. J Neurol Sci 235:45-54.
34. Seo JS, Leem YH, Lee KW, Kim SW, Lee JK, Han PL. 2010. Severe motor neuron degeneration in the spinal cord of the Tg2576 mouse model of Alzheimer disease. J Alzheimers Dis 21:263-276.
35. Stephan A, Laroche S, Davis S. 2001. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J Neurosci 21:5703-5714.
36. Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Piña-Crespo JC, Lipton SA. 2013. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A 110:E2518-E2527.
37. Townsend M, Mehta T, Selkoe DJ. 2007. Soluble A beta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282:33305-33312.
38. Van Den Bosch L, Robberecht W. 2000. Different receptors mediate motor neuron death induced by short and long exposures to excitotoxicity. Brain Res Bull 53:383-388.
39. Von Koch CS, Zheng H, Chen H, Trumbauer M, Thinakaran G, Van der Ploeg LH, Price DL, Sisodia SS. 1997. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol Aging 18:661-669.
40. Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, Zhao NM, Dominguez B, Lee KF, Gan WB, Zheng H. 2005. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-like protein 2. J Neurosci 25:1219-1225.
41. Wirths O, Weis J, Kayed R, Saido TC, Bayer TA. 2007. Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging 28:1689-1699.
42. Yankner BA, Duffy LK, Kirschner DA. 1990. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250:279-282.
43. Zhou Q, Sheng M. 2013. NMDA receptors in nervous system diseases. Neuropharmacology 74:69-75.